Disease · MONDO_0012268

AIDS

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. AIDS. Diseases, record MONDO_0012268. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0012268

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: AIDS; Open Targets
Open Targets ID: MONDO_0012268; Open Targets
Other names: ACQUIRED IMMUNE DEFIC SYNDROME, ACQUIRED IMMUNO DEFIC SYNDROME, ACQUIRED IMMUNODEFIC SYNDROME, AIDS (disorder), AIDS - Acquired immunodeficiency syndrome, AIDS, NOS, Acquired Immuno Deficiency Syndrome, Acquired Immuno-Deficiency Syndromes, Acquired Immunodeficiency Syndromes, Acquired human immunodeficiency virus infection syndrome NOS, Acquired immune defic. syndr., Acquired immune deficiency syndrome (AIDS), Acquired immune deficiency syndrome (AIDS) (disorder), Acquired immune deficiency syndrome, NOS, Acquired immunodeficiency syndrome, Acquired immunodeficiency syndrome, NOS, IMMUNODEFIC SYNDROME ACQUIRED, IMMUNOL DEFIC SYNDROME ACQUIRED, Immuno-Deficiency Syndrome, Acquired, Immuno-Deficiency Syndromes, Acquired, Immunodeficiency Syndrome, Acquired, Immunodeficiency Syndromes, Acquired, Immunodeficiency due to human immunodeficiency virus infection, Immunologic Deficiency Syndrome, Acquired, Syndrome, Acquired Immuno-Deficiency, Syndrome, Acquired Immunodeficiency, Syndromes, Acquired Immuno-Deficiency, Syndromes, Acquired Immunodeficiency, acquired human immunodeficiency virus infection syndrome NOS (disorder), acquired immune deficiency, acquired immune deficiency syndrome, acquired immunedeficiency syndrome, acquired immunodeficiency disease, acquired immunodeficiency syndrome, AIDS; Open Targets
Disease Ontology: DOID:635; Disease Ontology
MeSH: D000163; MeSH
NCI Thesaurus: C2851; NCI Thesaurus
Highest stage of its drugs: Approval, for 5 of its 108 drugs, from DailyMed, PMDA and TTD; Open Targets

Drugs108

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DOXORUBICIN HYDROCHLORIDE	CHEMBL359744	Small molecule	Approval	PMDA	3	2	2	Drugs and targets
VALGANCICLOVIR HYDROCHLORIDE	CHEMBL1200454	Small molecule	Approval	DailyMed and PMDA	3	0	0	Drugs and targets
GANCICLOVIR SODIUM	CHEMBL1200850	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
LEXGENLEUCEL-T	CHEMBL2107847	Cell	Approval	TTD	1	0	0	Drugs and targets
MEGESTROL ACETATE	CHEMBL1201139	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
ZIDOVUDINE	CHEMBL129	Small molecule	Phase 3	ClinicalTrials.gov	42	42	42	Drugs and targets
DIDANOSINE	CHEMBL1460	Small molecule	Phase 3	ClinicalTrials.gov	16	16	15	Drugs and targets
ZALCITABINE	CHEMBL853	Small molecule	Phase 3	ClinicalTrials.gov	11	11	11	Drugs and targets
ALDESLEUKIN	CHEMBL1201438	Protein	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
STAVUDINE	CHEMBL991	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets

1 to 10 of 108

See all 108 drugs

Targets129

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
EPOR	Erythropoietin receptor	3	Erythropoietin receptor agonist	Phase 1	https://conductscience.org/library/genes/2057	Drugs and targets
IFNAR1	Interferon alpha/beta receptor	3	Interferon alpha/beta receptor agonist	Phase 3	https://conductscience.org/library/genes/3454	Drugs and targets
IFNAR2	Interferon alpha/beta receptor	3	Interferon alpha/beta receptor agonist	Phase 3	https://conductscience.org/library/genes/3455	Drugs and targets
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
TUBA1A	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets

1 to 10 of 129

See all 129 targets

Trials121

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00004978	An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy	Phase 3	4,150	2011-04-25	HIV Infections	ALDESLEUKIN	Its record names the disease	ClinicalTrials.gov
NCT00013611	Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)	Phase 3	1,695	2010-12-13	HIV Infection	ALDESLEUKIN	Its record names the disease	ClinicalTrials.gov
NCT04253119	ART First-line Treatment Durability in Russia		536	2024-04-17	HIV-1-infection	ATAZANAVIR, DARUNAVIR, EFAVIRENZ, ETRAVIRINE, FOSAMPRENAVIR, LOPINAVIR, NEVIRAPINE, RILPIVIRINE	Its record names the disease	ClinicalTrials.gov
NCT00608569	Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults	Not applicable	529	2013-11-15	HIV Infections	EMTRICITABINE, EMTRICITABINE, (+/-)-, LOPINAVIR, RITONAVIR, TENOFOVIR DISOPROXIL FUMARATE	Its record names the disease	ClinicalTrials.gov
NCT01435018	Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS	Phase 3	334	2019-04-08	HIV-1 Infection	BLEOMYCIN, EFAVIRENZ, EMTRICITABINE, EMTRICITABINE, (+/-)-, ETOPOSIDE, PACLITAXEL, TENOFOVIR DISOPROXIL FUMARATE, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT00000134	Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)	Phase 3	279	2015-09-14	HIV Infections, Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis	FOSCARNET, GANCICLOVIR	Its record names the disease	ClinicalTrials.gov
NCT01837277	Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS Patients	Phase 2/3	186	2023-12-14	Severely Immunocompromised HIV Patients	DOLUTEGRAVIR, EFAVIRENZ	Its record names the disease	ClinicalTrials.gov
NCT00267865	Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma	Phase 2	12	2020-05-01	AIDS-Related-Primary Central Nervous System Lymphoma	LEUCOVORIN, METHOTREXATE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00000841	A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months	Phase 3	1,750		HIV Infections	INDINAVIR SULFATE, LAMIVUDINE, ZIDOVUDINE	Its record names the disease	ClinicalTrials.gov
NCT00000979	Comparison of ddI Versus Zidovudine in HIV-Infected Patients	Phase 2	1,500		HIV Infections	DIDANOSINE, ZIDOVUDINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 121

See all 121 trials

Comparisons in its trials23

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
rIL-2 vs No rIL-2: Grade 4 Signs and Symptoms	466 of 2,071	383 of 2,040	4,111	NCT00004978	Trial comparisons
rIL-2 vs No rIL-2: Number of Participants With Changes in Anti-retroviral Treatment (ART)	1,760 of 2,071	1,751 of 2,040	4,111	NCT00004978	Trial comparisons
rIL-2 vs No rIL-2: Number of Participants Who Died From Any Cause	107 of 2,071	116 of 2,040	4,111	NCT00004978	Trial comparisons
rIL-2 vs No rIL-2: Hepatic, Metabolic, and Cardiac Conditions	134 of 2,071	136 of 2,040	4,111	NCT00004978	Trial comparisons
rIL-2 vs No rIL-2: New or Recurrent Serious HIV Disease Progression Event Including Death	126 of 2,071	130 of 2,040	4,111	NCT00004978	Trial comparisons
rIL-2 vs No rIL-2: New or Recurrent HIV Disease Progression Event Including Death	159 of 2,071	165 of 2,040	4,111	NCT00004978	Trial comparisons
rIL-2 vs No rIL-2: Participants With a New Disease Progression Event or Death	154 of 2,071	164 of 2,040	4,111	NCT00004978	Trial comparisons
rIL-2 vs No rIL-2: serious adverse events	466 of 2,071	383 of 2,040	4,111	NCT00004978	Trial comparisons
rIL-2 vs No rIL-2: Pattern of Use of Prophylaxis for Opportunistic Infections	54 of 2,028	53 of 2,005	4,033	NCT00004978	Trial comparisons
Proleukin Plus Antiretroviral Therapy vs Antiretroviral Therapy Only: New or Recurrent Disease Progression Events, as Defined, or Death.	110 of 849	119 of 846	1,695	NCT00013611	Trial comparisons

1 to 10 of 23

See all 23 comparisons in its trials

Papers from its trials40

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32145827	RESULT	1	PubMed
20547574	RESULT	1	PubMed
19828532	RESULT	2	PubMed
18073252	RESULT	1	PubMed
16547789	RESULT	1	PubMed
16192247	RESULT	1	PubMed
15892437	RESULT	1	PubMed
15736019	RESULT	1	PubMed
15206062	RESULT	1	PubMed
15002082	RESULT	1	PubMed

1 to 10 of 40

See all 40 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0012268

GET https://conductscience.org/api/diseases/v1/MONDO_0012268/drugs?page=2

API reference For AI assistants